Dr Mehmet Toner , director of the BioMicroElectroMechanical Systems Resource Center in Massachusetts General ' s Center for Engineering in Medicine , says while it will take at least five years before the test is on the market , it ' s another step toward personalized medicine and the implications for patients are significant . " It is very big . It has the potential to turn cancer into a chronic disease , because we can monitor patients individually and respond with treatment to the genetic makeup of their cancer . "
